Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Evergreen Theragnostics developed a pipeline of diagnostic and therapeutic radiopharmaceuticals, including Octevy for neuroendocrine tumor imaging (NDA under FDA review) and EVG321 radioligand therapies in early clinical stages for small cell lung cancer. The company's Springfield, NJ site was a state-of-the-art, cGMP facility for commercial and clinical manufacturing, supporting internal pipeline and CDMO contracts. In July 2025, the company was acquired by Lantheus for $250M upfront plus milestones, integrating all operations and programs.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Evergreen Pharmaceutical.